Downloads
Abstract
Objectives:
1) To study effectiveness of highdose chemotherapy combined with targeted therapy in treatment of late stage and recurrent ovarian cancer.
2) To study effectiveness of peripheral autologous stem cells transplantation in supporting patients after highdose chemotherapy.
Materials: 11 patients with late stage and recurrent ovarian cancer.
Methods: a serial-case study.
Results: Mean age of patients was 49.2±5.2, 4 patients had two cycles while 7 had one cycle. Mean time of completely normalization of white blood cells was 7.6±0.8 days, platelet was 9.6±2.2 days. Progressive free survival and overall survival were 19.3±5.6 months and 31.0±6.2 months, respectively.
Conclusions: High-dose chemotherapy combined with targeted is safe and effective in treatment of late stage and recurrent ovarian cancer.
References
Bengala C, Guarneri V, Ledermann J, Rosti G, Wandt H, et al (2005) High-dose chemotherapy with autologous haemopoietic support for advanced ovarian cancer in first complete remission: retrospective analysis from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT), Bone Marrow Transplantation, 36: 25-31.
Bensinger WI (2004) High-dose Preparatory Regimens, Thomas’ Hematopoietic Cell Transplantation: Stem Cell Transplantation, 4ᵗʰ Edition, 316-332.
Castonguay V, Wilson MK, Diaz-Padilla ID, Wang L, Oza AM (2015) Estimation of Expectedness: Predictive Accuracy of Standard Therapy Outcomes in Randomized Phase 3 Studies in Epithelial Ovarian Cancer, Cancer, 121: 413-422.
Chan S, Griffin M, Stewarty J, Gregoryzx K, Hughes A, et al (2007) Modern Chemotherapy Management of Recurrent Ovarian Cancer: A Multicentre Study, Clinical Oncology, 19: 129-134.
Chase DM, Gibson SJ, Monk BJ, Tewari KS (2013) Updates on Anti-Cancer Therapy in Ovarian Cancer, Chemotherapy, 2(1): 109-117.
Chobanian N, Dietrich CS (2008) Ovarian cancer, Surg Clin North Am, 88(2): 285-299.
Doroshow JH, Synold T (2007) Pharmacologic Basis for High-Dose Chemotherapy, Thomas’ Hematopoietic Cell Transplantation, Third Edition, 130-157.
Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R (2015) Optimal primary surgical treatment for advanced epithelial ovarian cancer (Review), Cochrane Database of Systematic Reviews, CD007565.
Gabra H, Blagden S (2012) Epithelial Ovarian Cancer, Dewhurst’s Textbook of Obstetrics & Gynaecology, Eighth Edition, 760-775.
Jaaback K, Johnson N, Lawrie TA (2016) Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer (Review), Cochrane Database of Systematic Reviews, CD005340.
Legros M, Dauplat J, Fleury J et al (1997) High-Dose Chemotherapy With Hematopoietic Rescue in Patients With Stage III to IV Ovarian Cancer: Long-Term Results, J Clin Oncol, 15: 1302-1308.
Levin KL, Hryniuk WM (1987) Dose Intensity Analysis of Chemotherapy Regimens in Ovarian Carcinoma, J Clin Oncol, 5: 756-767.
Möbus V, Wandt H, Frickhofen N, Bengala C, Champion K, et al (2007) Phase III Trial of High-Dose Sequential Chemotherapy With Peripheral Blood Stem Cell Support Compared With Standard Dose Chemotherapy for First-Line Treatment of Advanced Ovarian Cancer: Intergroup Trial of the AGO-Ovar/AIO and EBMT, J Clin Oncol, 25: 4187-4193.
Rauh-Hain JA, Del Carmen MG (2013) Recurrent Epithelial Ovarian Cancer: An Update on Treatment, Cancer Network, 1-10.
Salerno MG, Ferrandina G, Greggi S, Pierelli L, Menichella G, et al (2001) High-dose chemotherapy as a consolidation approach in advanced ovarian cancer: long-term results, Bone Marrow Transplantation, 27: 1017-1025.
| Published | 19-08-2016 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 36 (2016) | |
| Section | Original article | |
| DOI | ||
| Keywords | high-dose chemotherapy, peripheral autologous stem cells transplatation, epithelial ovarian cancer |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Journal of Clinical Medicine Hue Central Hospital